2seventy bio, Inc.

Equities

TSVT

US9013841070

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 28/06/2024 am IST			5-day change	1st Jan Change
3.76 ^USD	+4.44%		0.00%	-11.94%

26/06	2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours	MT
26/06	2seventy Bio Sells Gene Editing Therapy To Novo Nordisk for Up To $40 Million	DJ

Engine Capital Nominates Candidates to the Board of 2seventy bio

March 21, 2024 at 02:54 am IST

On March 20, 2024, 2seventy bio, Inc. announced that Engine Capital LP nominated 2 candidates, Robert Frankfurt and David Sgro, for election to the Board at the Company?s 2024 annual meeting of stockholders.

Latest news about 2seventy bio, Inc.

2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours	27/06	MT
2seventy Bio Sells Gene Editing Therapy To Novo Nordisk for Up To $40 Million	27/06	DJ
Transcript : 2seventy bio, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 01:20 PM	10/06
Top Midday Decliners	06/06	MT
Goldman Sachs Downgrades 2seventy bio to Sell From Neutral, Adjusts Price Target to $2 From $5	06/06	MT
Earnings Flash (TSVT) 2SEVENTY BIO Reports Q1 Revenue $12.4M, vs. Street Est of $14.1M	08/05	MT
Transcript : 2seventy bio, Inc., Q1 2024 Earnings Call, May 08, 2024	08/05
2seventy bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
US FDA mandates label updates on CAR-T cancer therapies	19/04	RE
Engine Capital Withdraws Nominations to 2seventy bio Board	09/04	CI
Bristol-Myers Squibb, 2seventy Bio Say FDA Approves Expansion of Myeloma Treatment's Indication	05/04	MT
Bristol Myers, 2seventy Get FDA OK for Earlier Abecma Use in Multiple Myeloma	05/04	DJ
Bristol Myers: FDA approves Abecma in multiple myeloma	05/04	CF
US FDA allows expanded use of Bristol Myers' cell therapy for blood cancer	05/04	RE
U.S. FDA allows expanded use of Bristol Myers' cell therapy	05/04	RE
U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio?S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy	05/04	CI
Regeneron Pharmaceuticals, Inc. completed the acquiistion of R&D pipeline from 2seventy bio, Inc..	01/04	CI
Regeneron Pharmaceuticals, Inc. completed the acquiistion of R&D pipeline from 2seventy bio, Inc. for $15 million.	01/04	CI
Bristol Myers Squibb Gets EU OK for Cancer Treatment	21/03	DJ
Engine Capital Nominates Candidates to the Board of 2seventy bio	21/03	CI
2seventy bio, Inc. Announces Board Appointments	21/03	CI
Top Premarket Gainers	18/03	MT
2seventy Bio Shares Soar Premarket as FDA Panel Backs Abecma	18/03	DJ
Bristol Myers, 2seventy Bio's Cancer Treatment Wins FDA Committee Approval	16/03	DJ
FDA Advisory Committee Votes in Favor of Bristol-Myers Squibb Company and 2seventy bio, Inc. Abecma for Triple-Class Exposed Multiple Myeloma in Further Lines of Therapy	16/03	CI

Chart 2seventy bio, Inc.

Duration

Period

More charts

Company Profile

2seventy bio, Inc. is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The Company is focused on the commercialization and development of Abecma (idecabtagene vicleucel). Abecma is its B cell maturation antigen (BCMA)-targeted CAR T cell therapy for multiple myeloma, in collaboration with their partner Bristol Myers Squibb (BMS). ABECMA is a BCMA-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Abecma uses a lentiviral vector (LVV), to deliver a chimeric antigen receptor (CAR), with the potential to program a patientâs own T cells to recognize the plasma cell specific BCMA, protein on the cell surface.

Sector

Biotechnology & Medical Research

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for 2seventy bio, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.76 USD

Average target price

9.8 USD

Spread / Average Target

+160.64%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
2SEVENTY BIO, INC.	-11.94%	185M
MODERNA, INC.	+21.85%	46.93B
LONZA GROUP AG	+37.63%	39.08B
IQVIA HOLDINGS INC.	-8.05%	38.48B
ALNYLAM PHARMACEUTICALS, INC.	+29.04%	31.01B
CELLTRION, INC.	-13.75%	26.14B
ICON PUBLIC LIMITED COMPANY	+10.65%	25.88B
MEDPACE HOLDINGS, INC.	+38.43%	12.53B
BIO-TECHNE CORPORATION	-6.92%	11.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-12.29%	10.65B

Other Biotechnology & Medical Research